Wolfram Doehner1,2, Hertzel C Gerstein3, Janina Ried4, Hyejung Jung3, Christian Asbrand4, Sibylle Hess4, Stefan D Anker1,2. 1. Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany. 2. Division of Cardiology and Metabolism, Department of Cardiology (Virchow Hospital), German Centre for Cardiovascular Research (DZHK), Partner Site Berlin and Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany. 3. Population Health Research Institute, McMaster University, Hamilton Health Sciences, L8S 4K1 Hamilton, ON, Canada. 4. Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.
Abstract
AIMS: The association of body weight and weight change with mortality and cardiovascular (CV) outcome in patients with diabetes mellitus (DM) is not clearly established. We assessed the relationship between weight, weight change, and outcomes in patients with established CV risk factors and type 2 DM or pre-diabetes. METHODS AND RESULTS: A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI) < 22 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40 kg/m2, respectively). Outcome variables included total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization. Follow-up was 6.2 years (interquartile range 5.8-6.7 years). After multivariable adjustment, lowest risks were seen in patients with overweight and mild obesity for total mortality [overweight: hazard ratio (HR) 0.80 (95% confidence interval (CI) 0.69-0.91); obesity Grade 1: HR 0.82 (0.71-0.95), both P < 0.01)] and CV mortality [overweight: HR 0.79 (0.66-0.94); obesity Grade 1: 0.79 (0.65-0.95), all compared to patients with normal BMI, P < 0.05]. Obesity of any severity was not associated with higher mortality. Low body weight was related to higher mortality [HR 1.28 (1.02-1.61); CV mortality: HR 1.34 (1.01-1.79), P < 0.05]. A continued 2-year weight loss was associated with higher risk of mortality [HR 1.32 (1.18-1.46), P < 0.0001] and CV mortality [HR 1.18 (1.02-1.35), compared to patients without weight loss, P < 0.05]. In turn, weight gain was not related to any adverse outcome. CONCLUSION: Obesity in patients with DM or pre-diabetes and CV risk profile was not associated with higher mortality or adverse CV outcome. The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2). Weight loss was an independent risk factor for higher mortality compared to no weight loss.
AIMS: The association of body weight and weight change with mortality and cardiovascular (CV) outcome in patients with diabetes mellitus (DM) is not clearly established. We assessed the relationship between weight, weight change, and outcomes in patients with established CV risk factors and type 2 DM or pre-diabetes. METHODS AND RESULTS: A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI) < 22 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40 kg/m2, respectively). Outcome variables included total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization. Follow-up was 6.2 years (interquartile range 5.8-6.7 years). After multivariable adjustment, lowest risks were seen in patients with overweight and mild obesity for total mortality [overweight: hazard ratio (HR) 0.80 (95% confidence interval (CI) 0.69-0.91); obesity Grade 1: HR 0.82 (0.71-0.95), both P < 0.01)] and CV mortality [overweight: HR 0.79 (0.66-0.94); obesity Grade 1: 0.79 (0.65-0.95), all compared to patients with normal BMI, P < 0.05]. Obesity of any severity was not associated with higher mortality. Low body weight was related to higher mortality [HR 1.28 (1.02-1.61); CV mortality: HR 1.34 (1.01-1.79), P < 0.05]. A continued 2-year weight loss was associated with higher risk of mortality [HR 1.32 (1.18-1.46), P < 0.0001] and CV mortality [HR 1.18 (1.02-1.35), compared to patients without weight loss, P < 0.05]. In turn, weight gain was not related to any adverse outcome. CONCLUSION:Obesity in patients with DM or pre-diabetes and CV risk profile was not associated with higher mortality or adverse CV outcome. The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2). Weight loss was an independent risk factor for higher mortality compared to no weight loss.
Authors: Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler Journal: Eur Heart J Date: 2020-01-07 Impact factor: 29.983
Authors: Louise Bordeleau; Natalia Yakubovich; Gilles R Dagenais; Julio Rosenstock; Jeffrey Probstfield; Pan Chang Yu; Lars E Ryden; Valdis Pirags; Giatgen A Spinas; Kare I Birkeland; Robert E Ratner; Jose A Marin-Neto; Matyas Keltai; Matthew C Riddle; Jackie Bosch; Salim Yusuf; Hertzel C Gerstein Journal: Diabetes Care Date: 2014-02-26 Impact factor: 19.112
Authors: Edward Gregg; John Jakicic; George Blackburn; Paul Bloomquist; George Bray; Jeanne Clark; Mace Coday; Jeffrey Curtis; Caitlin Egan; Mary Evans; John Foreyt; Gary Foster; Helen Hazuda; James Hill; Edward Horton; Van Hubbard; Robert Jeffery; Karen Johnson; Abbas Kitabchi; William Knowler; Andrea Kriska; Wei Lang; Cora Lewis; Maria Montez; David Nathan; Rebecca Neiberg; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Bruce Redmon; Judith Regensteiner; Jack Rejeski; Paul Ribisl; Monika Safford; Kerry Stewart; Dace Trence; Thomas Wadden; Rena Wing; Susan Yanovski Journal: Lancet Diabetes Endocrinol Date: 2016-08-30 Impact factor: 32.069
Authors: Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto Journal: Lancet Date: 2009-03-18 Impact factor: 79.321
Authors: Jinbo Hu; Yang Hu; Ellen Hertzmark; Chen Yuan; Gang Liu; Meir J Stampfer; Eric B Rimm; Frank B Hu; Molin Wang; Qi Sun Journal: J Clin Endocrinol Metab Date: 2022-02-17 Impact factor: 5.958
Authors: Louisa Schaller; Michael Arzt; Bettina Jung; Carsten A Böger; Iris M Heid; Stefan Stadler Journal: Front Neurol Date: 2021-12-02 Impact factor: 4.003
Authors: Claes Held; Nermin Hadziosmanovic; Philip E Aylward; Emil Hagström; Judith S Hochman; Ralph A H Stewart; Harvey D White; Lars Wallentin Journal: J Am Heart Assoc Date: 2022-01-21 Impact factor: 6.106
Authors: Ralph K Akyea; Wolfram Doehner; Barbara Iyen; Stephen F Weng; Nadeem Qureshi; George Ntaios Journal: J Cachexia Sarcopenia Muscle Date: 2021-09-27 Impact factor: 12.910